Pharma majors bet big on next-gen cancer therapies as Merck and AstraZeneca invest billions in innovative oncology assets.
Roche is advancing autonomous AI labs by combining artificial intelligence, robotics and laboratory automation to transform pharmaceutical drug R&D.
Digital tools and artificial intelligence could accelerate Ayush’s growth, helping India build a stronger pathway toward the USD 318 billion goal by 2047.
Sterile injectable CDMOs in India are expanding their capabilities in fill-finish operations, advanced technologies, regulatory compliance, and the manufacturing of complex drugs.
AI drug discovery is gaining ground in India's pharmaceutical R&D landscape, with Rasayan Labs and ICT Mumbai bringing computational chemistry, molecular design and synthesis planning into a unified drug-discovery workflow.
InnoCare and Eli Lilly have signed drug discovery pacts worth up to 3.35 billion, strengthening global interest in Chinese innovation.
Claude AI uncovers a novel enzyme system with CRISPR-like features, marking Anthropic’s first public biology research result and expanding AI-driven biological discovery.
Today in Pharma highlights major deals and alliances, from Novartis’ radioligand therapy agreement with BoomRay to IMA and Abbott’s adult immunization drive.
India renews its global pledge on hepatitis elimination, reaffirming its commitment to end Hepatitis B through prevention, treatment, and equitable care.
AbbVie joins the AI drug-discovery race with Iambic, applying advanced molecular AI to accelerate small-molecule discovery across core therapeutic areas.
.jpg)
, CDSCO.jpg)
